🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 67% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size
120 Servings
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

15 mg (80% DV)
✅ 1.1× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 15mg UL 35mg
100 mcg (80% DV)
✅ 2.9× RDA — within safe limits 📚 197 studies (Tier A: 1, B: 55)
RDA 0.035mg This product: 0.1mg
Glutathione Precursor Complex
125 mg

Other Ingredients

Cellulose Gelatin Magnesium Stearate Silicon Dioxide

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) No Allergies

Product Information

📋 Directions for Use

For best results, NON-YEAST GTF should be taken on an empty stomach.

DIRECTIONS Take one to three capsules daily, one half hour before meals, or as directed by a physician.

🧪 Formulation Notes

This product contains no preservatives to ensure maximal tolerance and absorption.

Hypoallergenic

Additional Information

10080747

NON-YEAST GTF is a scientifically designed dietary supplement containing a highly bio-available form of trivalent chromium in solution with all other identified constituents of glucose tolerance factor.

The dosage of chromium reflect the elemental yield.

ECOLOGICAL FORMULAS

NON-YEAST GTF is well tolerated by exquisitely sensitive individuals for whom other sources of chromium are normally contraindicated. The nutrients are bound and do not occur in the free form.

EXP0813

Product Details

DSLD Entry Date 2013-06-25
Product Type Other Combinations
Form Capsule
DSLD ID 22897
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →